ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

QUILLIVANT XR
ADHD
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

QUILLIVANT XR CII

Generic Name and Formulations:
Methylphenidate HCl ext-rel 5mg/mL; pwd for oral susp after reconstitution.

Company:
Pfizer Inc.

Therapeutic Use:

Indications for QUILLIVANT XR:

Attention deficit hyperactivity disorder.

Adults and Children:

<6yrs: not established. ≥6yrs: Individualize. Shake bottle for 10 secs before use. Initially 20mg once daily in the AM. May increase by 10–20mg per week if needed; max 60mg daily.

Contraindications:

During or within 14 days of MAOIs.

Warnings/Precautions:

High potential for abuse and dependence; monitor. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder. Screen for risk factors in developing manic episode prior to initiating. Consider discontinuing if new psychotic or manic symptoms occur. Peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor growth (in children), BP, HR. Reduce dose or discontinue if paradoxical aggravation of symptoms occurs. Write ℞ for smallest practical amount. Reevaluate periodically. Pregnancy. Nursing mothers: monitor infants.

Interactions:

See Contraindications. Hypertensive crisis with MAOIs. Risk of serotonin syndrome with serotonergic drugs.

Pharmacological Class:

CNS stimulant.

Adverse Reactions:

Appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, hypertension; priapism.

Metabolism:

Hepatic.

Elimination:

Renal.

Generic Availability:

NO

How Supplied:

Bottles (w. oral dosing dispenser)—60mL, 120mL, 150mL, 180mL

Sign Up for Free e-newsletters